MedPage Today3d
FDA Says Compounded Tirzepatide Must Exit the Market
Approved in 2022 for type 2 diabetes and in 2023 for chronic weight management along with diet and exercise, tirzepatide is ...
Daily12h
Tirzepatide taken for weight loss may lead to Colonic Ischemia: Case report
A recent case published in the journal ACG CASE REPORTS JOURNAL found a possible risk of colonic ischemia caused by the usage ...
The National Law Review2d
GLP-1 Drugs: FDA “Re-Confirms” Decision Removing Tirzepatide from the Drug Shortage List
On December 19, 2024, the U.S. Food and Drug Administration (FDA) issued a Declaratory Order reevaluating and re-confirming ...
FiercePharma3d
FDA reaffirms decision to erase Eli Lilly's tirzepatide from shortage list, halting future flow of knockoffs
The FDA has doubled down on its decision to remove Eli Lilly’s tirzepatide from its list of products that are in shortage. | ...
Too Old to Operate2d
Lower Risk of Cardiovascular Death with Tirzepatide in Heart Failure
The following is a summary of “Tirzepatide for Heart Failure with Preserved Ejection Fraction and Obesity,” published in the ...
Investing3d
Hims & Hers shares tumble as FDA resolves obesity drug shortage
The FDA's latest decision could reshape the market dynamics for obesity drugs, as compounded versions were allowed under U.S. regulations during the shortage. Hims & Hers Health's stock movement today ...
Tennessee woman accused of selling fake weight loss drugs as counterfeit concerns grow
The woman was accused of selling counterfeit versions of popular weight loss drugs, including Ozempic and Wegovy. Experts say ...
BioSpace4d
FDA Issues Warning Letters Against GLP-1 Compounders
The letters come amid the Outsourcing Facilities Association’s ongoing lawsuit against the FDA over the regulator’s decision ...